RankingsComparison
Wegovy vs Zepbound: labels, evidence, and price paths
A side-by-side of Wegovy (semaglutide) and Zepbound (tirzepatide): FDA labels, key trials, and manufacturer self-pay—not medical advice.
Updated October 26, 2026.
Medical disclaimer: Not medical advice. Your clinician chooses therapy based on your history, contraindications, and goals. Both medicines carry boxed warnings about thyroid C-cell tumors in their labels.
Snapshot
| Wegovy (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Obesity label | Yes (adults; ages 12+ for obesity per label) | Yes (adults with obesity or overweight + comorbidity) |
| Other labeled uses (high level) | CV risk reduction; MASH accelerated approval language on current label | Moderate to severe OSA in adults with obesity |
| Weekly injectable maintenance (typical label framing) | 1.7 or 2.4 mg (plus newer presentations on current label) | 5, 10, or 15 mg for weight; 10 or 15 mg for OSA |
| List / WAC (Novo page) | $1,349.02 / package (novopricing) | See Lilly Zepbound pricing info |
| Published self-pay entry points | From $199/mo intro pens / $149 pill tiers via Novo programs | From $299/mo (2.5 mg) via LillyDirect messaging |
Always confirm the PDF label for the product in your hand: Wegovy label, Zepbound label.
Evidence anchors (not a head-to-head verdict for you)
- Wegovy / STEP 1: Once-weekly semaglutide 2.4 mg vs placebo in adults with overweight/obesity (PubMed 33567185).
- Zepbound / SURMOUNT-1: Tirzepatide vs placebo for obesity (PubMed 35658024).
Manufacturer-sponsored indirect comparisons exist in the news cycle; they are not a substitute for the labeled trials or your clinician’s judgment.
Price paths
Use manufacturer pages, not screenshot ads:
- Wegovy savings / self-pay: wegovy.com what to pay
- Zepbound LillyDirect / savings: lilly.com/lillydirect/medicines/zepbound, zepbound.lilly.com/savings
Government beneficiaries are usually excluded from commercial $25-style cards.
Who might discuss which with a clinician
This is not a recommendation—only discussion prompts:
- Need an obesity-labeled weekly option with long STEP program history → often Wegovy enters the conversation.
- Want a dual agonist with obesity + OSA labeled options and LillyDirect cash vials/pens → often Zepbound enters the conversation.
- Type 2 diabetes primary goal → Ozempic or Mounjaro labels may be more relevant than this obesity-focused pair.
Safety shared themes
Both labels discuss GI adverse reactions, gallbladder disease risk, hypoglycemia risk with insulin/secretagogues, and the boxed thyroid C-cell tumor warning. Read the Medication Guide that ships with the product.
Cross-links
- Cost tables → GLP-1 cost and pricing guide
- Broader ranking → Best FDA-approved GLP-1 drugs ranked
- Habits / side effects → glp1userguide.com
Sister living-with content: glp1userguide.com. Full dollar tables: GLP-1 cost and pricing guide.